Background. Muir-Torre syndrome (MTS) is a subtype of Lynch syndrome, which encompasses the combination of sebaceous skin tumours or keratoacanthomas and internal malignancy, due to mutations in DNA mismatch repair genes. Sebaceous neoplasms (SNs) may occur before other malignancies, and may lead to the diagnosis, which allows testing of other family members, cancer surveillance, risk-reducing surgery or prevention therapies. Aim. To evaluate the efficacy of universal immunohistochemistry (IHC) screening of SNs in a service setting. Methods. Patients with SNs were ascertained by a regional clinical pathology service over a 3-year period. Results of tumour IHC, clinical genetics notes and germline genetic testing were retrospectively reviewed. Results. In total, 62 patients presented with 71 SNs; 9 (15%) of these patients had previously diagnosed MTS. Tumour IHC was performed for 50 of the 53 remaining patients (94%); 26 (52%) had loss of staining of one or more mismatch repair proteins. Fifteen patients were referred to the Clinical Genetics department, and 10 patients underwent germline genetic testing. Two had a new diagnosis of MTS confirmed, with heterozygous pathogenic mutations detected in the MSH2 and PMS2 genes (diagnostic yield 20%). The PMS2 mutation was identified in a 57-year-old woman with a sebaceous adenoma and history of endometrial cancer; to our knowledge, this is the first time a PMS2 mutation has been reported in MTS. Conclusions. Universal IHC screening of SNs is an effective method to identify cases for further genetic evaluation. Rates of referral to clinical genetics were only moderate (58%). Increased awareness of MTS could help improve the rate of onward referral.
Introduction
Muir-Torre syndrome (MTS) is a subtype of Lynch syndrome (LS), characterized by the occurrence of sebaceous skin tumours or keratoacanthomas, together with internal malignancies. 1, 2 Sebaceous skin tumours are uncommon in the general population, but they occur in 9.2% of individuals and 28% of families with LS. 3 Other nongenetic risk factors include increasing age, male sex and immunosuppression. 4 Historically, MTS was a clinical diagnosis given to a patient with a sebaceous neoplasm (SN) and an internal malignancy. In this report, we use the term 'Muir-Torre syndrome/ Lynch syndrome' (MTS/LS) to refer to individuals with SNs and a pathogenic germline variant.
Lynch syndrome is caused by heterozygous mutations in DNA mismatch repair genes (MLH1, MSH2, MSH6 and PMS2), while MTS has been reported in patients with mutations in MSH2, 5 MLH1 and MSH6. 6 The identification of LS has important implications for the patient and their family, as it is associated with a high risk of colorectal and endometrial cancer, and with moderate risks for malignancies of the ovary, stomach, biliary tract, pancreas, urinary tract and central nervous system. 7 Predictive genetic testing can be offered to identify relatives with the condition; LS mutation carriers benefit from enhanced cancer surveillance (1-to 2-yearly colonoscopy) while prevention options include risk reducing surgery (hysterectomy and/or bilateral salpingo-oophorectomy) and pharmacological treatment with long-term aspirin. 8 Universal immunohistochemical screening of SNs has been suggested, 9 and was found to be effective in identifying patients for germline genetic testing of mismatch repair genes in a study at two academic cancer centres, with 29% of 86 patients being diagnosed with MTS/LS. 10 Systematic testing using tumour immunohistochemistry (IHC) or microsatellite instability has been shown to have clinical utility in patients aged ≤ 70 years diagnosed with colorectal 11 or endometrial 12 cancer. While this approach is more sensitive than selective testing (for example using the revised Bethesda criteria), one challenge is that the uptake of genetic counselling may be low. 13 In view of this, we assessed the effectiveness of universal IHC screening of SNs to identify MTS cases in a service setting covering a defined geographical population.
Methods
Patients with a diagnosis of sebaceous carcinoma, sebaceous adenoma or sebaceoma were identified through the Histopathology Department at Addenbrooke's Hospital, which covers the West Anglia region of the UK (population approximately 1 million) 14 from October 2012 to October 2015. Patients with sebaceous hyperplasia only were not selected.
It was routine clinical practice for tumour IHC to be performed on all SNs. Samples were sent for IHC from six district general hospitals to the regional centre. IHC was performed on coated slides (Leica Microsystems, Milton Keynes, Buckinghamshire, UK) using mouse antibodies: anti-MLH1, anti-MSH2, anti-MSH6 and anti-PMS2 (all Dako, Glostrup, Denmark). PCRbased microsatellite instability testing was not performed unless specifically requested by a clinician. Histopathology reports highlighted the possibility of MTS/LS. Clinical information including age, tumour location and subtype, and personal and family history of cancer (if documented) were recorded for each patient. Patients who were referred to the Clinical Genetics department were sent a family history form and seen within 3 months. Three-generation family histories were evaluated for cancer diagnoses. Genetic testing was performed in accredited NHS molecular genetics laboratories, using next-generation sequencing and multiplex ligation-dependent probe amplification (MLPA) for MLH1, MSH2 and MSH6, and Sanger sequencing and MLPA for PMS2. Patients gave informed written consent for genetic testing. The study used data that were generated as part of routine clinical care, and institutional review board approval was not required. Informed consent for publication was obtained from the patient with a truncating PMS2 mutation whose history is described in detail below.
Results

Patient demographics and tumour types
In total, 62 individuals with 71 SN samples were referred for histological analysis; 57 of these patients had a single SN, 2 patients had 2 SNs, 2 patients had 3 SNs and 1 patient had 4 SNs. Mean age of the patients was 70 years (range 23-92 years), and 43 (69%) were male.
The 71 SNs comprised 41 sebaceous adenomas, 21 sebaceomas, 7 sebaceous carcinomas, 1 cystic sebaceoma and 1 undetermined sebaceous tumour, and 51 (72%) of the 71 SNs were located on the head and neck.
Medical history and immunohistochemistry results
Of the 62 patients, 9 (15%) had previously diagnosed MTS/LS, and 1 had a family history of LS. Notes were reviewed for eight families who were seen in our Clinical Genetics department (two had mutations in MLH1, four in MSH2 and two in MSH6). Two patients gave a history of MTS/LS diagnosed at other centres, but their mutation reports were not available for this study (Fig. 1) .
Tumour IHC for mismatch repair (MMR) proteins was performed for 50 of the 53 remaining patients (94%). The reason for omitting tumour IHC for the other three was not clear from the records.
Of the 50 samples, 26 (52%) had loss of staining of one or more MMR proteins; 19 showed loss of MSH2 and MSH6 staining (73%), 6 showed loss of MLH1 and PMS2 (23%), and 1 showed loss of MSH6 only (4%).
Genetic testing
Of the 26 patients with abnormal IHC (58%), 15 were referred to the Clinical Genetics department and 11 attended an appointment. The reasons for lack of referral for the other 11 patients were not clear from the records, although review of available notes suggested that some were discharged with no follow-up appointment or letter regarding their SN. Four patients were referred but did not attend their appointments (one was a renal transplant patient and one was already having colonoscopy screening due to a family history of MTS/LS).
Of the 11 patients who attended an appointment, 10 chose to have germline genetic testing. Two had a new diagnosis of MTS confirmed, with heterozygous pathogenic mutations detected in MSH2 . He had loss of MLH1 and PMS2 staining on tumour IHC, and no significant family history of cancer. The remaining seven patients had no mutations detected; five of these had no significant personal or family history of cancer, one had a parent with bowel cancer at 80 years and one had a cousin with endometrial/ovarian cancer.
The PMS2 mutation was identified in the heterozygous state in a 57-year old woman, who presented to her local dermatology clinic with a skin tumour on the right side of her jaw, clinically suspected to be a papilloma. She had a personal history of endometrial cancer aged 53 years [grade 1, Federation Internationale de Gynecologie et d'Obstetrique classification (FIGO) stage 1a endometrioid adenocarcinoma] treated with hysterectomy. She had a family history of breast cancer in her mother and two maternal aunts, diagnosed in their 50s and 60s. There was no family history of bowel cancer. Excision biopsy showed a sebaceous adenoma with no evidence of malignancy. IHC of the sebaceous adenoma for MMR proteins showed loss of nuclear expression of PMS2 and faint focal staining for MLH1, while there was strong expression of MSH2 and MSH6 (Fig. 2) . The patient was seen by a clinical geneticist, and molecular testing was initiated. No mutations were detected in MLH1, MSH2 or MSH6, but additional testing for PMS2 a truncating mutation (Fig. 3) . MTS was diagnosed, and the patient commenced on 2-yearly colonoscopy screening, with normal results for the first colonoscopy.
The clinical features in of all the families with confirmed MTS/LS known to our Clinical Genetics department are summarized in Table 1 . In seven families, the proband had a strong personal and family history of LS-associated cancers (meeting the revised Bethesda criteria). One patient did not have a typical family history. His diagnosis of MTS/LS was made after IHC testing of a sebaceous carcinoma. However, one of his parents had been adopted, so the family history on that side of his family was not known.
Demographics were similar for the patients with MTS/LS (total of 11 patients, with 9 being previously diagnosed and 2 newly diagnosed; 31% female; mean age 66.6 years, range 56-80 years) and for the rest of the group (total of 51 patients, mean age 71.2 years, range 23-92 years). Of the five patients with multiple tumours, four had known MTS and one had abnormal tumour IHC with a family history of uterine cancer in a first-degree relative, but did not attend the genetics appointment. There was a suggestion that SNs located on areas other than the head and neck may be more likely to be associated with MTS (35% vs. 20%) but this was not statistically significant (Fisher exact test, P = 0.22).
Discussion
In this study, the proportion of SNs with loss of staining for one or more MMR proteins in our study was similar to that in the study of Everett et al. 10 (52% and 49%, respectively). The pattern of loss was also similar, with the majority showing loss of MSH2 and MSH6 in both our study and that of Everett et al. 10 (73% and 71%, respectively). However, significantly fewer new diagnoses of MTS were made in our study population, and this probably reflects the way in which the patients were ascertained. Everett et al. studied patients referred to the Clinical Genetics departments at two academic cancer centres and found germline MMR mutations confirming LS in 29% of their cohort, whereas we ascertained all patients with SNs diagnosed by a single regional histopathology department. A significant proportion (14%) of the patients had previously been diagnosed with MTS/LS, but only 56% of those with abnormal IHC were referred to the Clinical Genetics department, and 10 chose to have molecular testing, giving a diagnostic yield of 20%.
Our study differed from previous studies 15, 16 because there was IHC testing for a high proportion of cases (94%), and all patients with SNs who saw a genetic counsellor/clinical geneticist were offered molecular testing. A study using universal tumour testing in endometrial cancer found that uptake of genetic counselling was higher when patients were provided with an education document about the tumour tests as part of their preoperative information. 13 As SNs are usually diagnosed based on histopathology rather than clinical features, the dermatologist or plastic surgeon will need to review the family history, discuss the possibility of MTS and offer a referral to the Clinical Genetics department at a follow-up appointment. In the USA, cost or lack of insurance coverage may be a barrier to genetic counselling. 17 In our cohort, lack of referral by specialists rather than lack of uptake by patients was the main barrier to genetic testing. An alternative approach to universal IHC screening would be for clinicians to refer patients with SNs for genetic testing based on personal or family history of LS-associated malignancies. Looking at the clinical characteristics of our patients with MTS/LS (Table 1) , it is clear that most had a strong family history of malignancy. However, the diagnosis might have been missed in 2 out of the 10 using this approach.
In this study, we identified a patient with a truncating mutation in PMS2 and a history of endometrial cancer and sebaceous adenoma. To our knowledge, this is the first report of MTS in a patient with a truncating mutation in PMS2. One patient with an SN with normal IHC and a missense variant in PMS2 [c.137G>A, p.(Ser46Asn), according to NM_000535.5] has been reported previously. 10 This variant is of uncertain clinical significance (InSiGHT Class 3). Mutations in the PMS2 gene are associated with more modest increases in cancer risk compared with mutations in MLH1 and MSH2. 7, 18 This is reflected in the family history in our patient, who had a personal history of endometrial cancer but no family history of colorectal cancer. Universal screening will be particularly beneficial in identifying patients with MSH6 and PMS2 mutations who may be missed by targeted testing approaches.
Conclusion
Our study shows that universal IHC screening of SNs is useful in a service setting. The key challenge for this approach is ensuring that the patients identified as being at higher risk of having MTS are referred for genetic evaluation. Increased awareness of MTS among practising dermatologists and plastic surgeons, along with established multidisciplinary pathways, are needed to ensure that appropriate patients are referred. c.1021del ª 2018 British Association of Dermatologists
